Agency Information Collection Activities: Submission for OMB Review; Comment Request, 24752-24754 [2013-09913]
Download as PDF
<![CDATA[
24752
Federal Register / Vol. 78, No. 81 / Friday, April 26, 2013 / Notices
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned committee:
erowe on DSK2VPTVN1PROD with NOTICES
Times and Dates:
8:00 a.m.–5:00 p.m., June 13, 2013 (Closed)
8:00 a.m.–5:00 p.m., June 14, 2013 (Closed)
Place: Embassy Suites, 1900 Diagonal
Road, Alexandria, Virginia 22314,
Telephone: (703) 684–5900, Fax: (703) 684–
0653.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Purpose: The Safety and Occupational
Health Study Section will review, discuss,
and evaluate grant application(s) received in
response to the Institute’s standard grants
review and funding cycles pertaining to
research issues in occupational safety and
health, and allied areas.
It is the intent of NIOSH to support broadbased research endeavors in keeping with the
Institute’s program goals. This will lead to
improved understanding and appreciation for
the magnitude of the aggregate health burden
associated with occupational injuries and
illnesses, as well as to support more focused
research projects, which will lead to
improvements in the delivery of occupational
safety and health services, and the
prevention of work-related injury and illness.
It is anticipated that research funded will
promote these program goals.
Matters To Be Discussed: The meeting will
convene to address matters related to the
conduct of Study Section business and for
the study section to consider safety and
occupational health-related grant
applications. These portions of the meeting
will be closed to the public in accordance
with provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and the
Determination of the Director, Management
Analysis and Services Office, Centers for
Disease Control and Prevention, pursuant to
Section 10(d) Public Law 92–463.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information: Price
Connor, Ph.D., NIOSH Health Scientist, CDC,
2400 Executive Parkway, Mailstop E–20,
Atlanta, Georgia 30345, Telephone: (404)
498–2511, Fax: (404) 498–2571.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2013–09873 Filed 4–25–13; 8:45 am]
BILLING CODE 4163–18–P
VerDate Mar<15>2010
14:46 Apr 25, 2013
Jkt 229001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Subcommittee for Dose
Reconstruction Reviews (SDRR),
Advisory Board on Radiation and
Worker Health (ABRWH or the
Advisory Board), National Institute for
Occupational Safety and Health
(NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting for the
aforementioned subcommittee:
Time and Date: 9:00 a.m.–5:00 p.m.
Eastern Time, May 21, 2013.
Place: Cincinnati Airport Marriott, 2395
Progress Drive, Hebron, Kentucky 41018,
Telephone (859) 334–4611, Fax (859) 334–
4619.
Status: Open to the public, but without a
public comment period. To access by
conference call dial the following
information 1 (866) 659–0537, Participant
Pass Code 9933701.
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation Program
Act of 2000 to advise the President on a
variety of policy and technical functions
required to implement and effectively
manage the new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines that have
been promulgated by the Department of
Health and Human Services (HHS) as a final
rule; advice on methods of dose
reconstruction, which have also been
promulgated by HHS as a final rule; advice
on the scientific validity and quality of dose
estimation and reconstruction efforts being
performed for purposes of the compensation
program; and advice on petitions to add
classes of workers to the Special Exposure
Cohort (SEC).
In December 2000, the President delegated
responsibility for funding, staffing, and
operating the Advisory Board to HHS, which
subsequently delegated this authority to CDC.
NIOSH implements this responsibility for
CDC. The charter was issued on August 3,
2001, renewed at appropriate intervals, and
will expire on August 3, 2013.
Purpose: The Advisory Board is charged
with (a) providing advice to the Secretary,
HHS, on the development of guidelines
under Executive Order 13179; (b) providing
advice to the Secretary, HHS, on the
scientific validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advise the Secretary on
whether there is a class of employees at any
Department of Energy facility who were
exposed to radiation but for whom it is not
feasible to estimate their radiation dose, and
on whether there is reasonable likelihood
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
that such radiation doses may have
endangered the health of members of this
class. The Subcommittee for Dose
Reconstruction Reviews was established to
aid the Advisory Board in carrying out its
duty to advise the Secretary, HHS, on dose
reconstruction.
Matters to be Discussed: The agenda for the
Subcommittee meeting includes: dose
reconstruction program quality management
and assurance activities, including: current
findings from NIOSH internal dose
reconstruction blind reviews; and discussion
of dose reconstruction cases under review
(sets 8–9, and Savannah River Site, Rocky
Flats Plant, and Los Alamos National
Laboratory cases from sets 10–13).
The agenda is subject to change as
priorities dictate.
In the event an individual cannot attend,
written comments may be submitted. Any
written comments received will be provided
at the meeting and should be submitted to
the contact person below well in advance of
the meeting.
Contact Person for More Information:
Theodore M. Katz, M.P.A., Designated
Federal Officer, NIOSH, CDC, 1600 Clifton
Road, NE., Mailstop E–20, Atlanta, Georgia
30333, Telephone (513) 533–6800, Toll Free
1–800–CDC–INFO, Email ocas@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2013–09877 Filed 4–25–13; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifiers CMS–685, CMS–
10436, CMS–10452, CMS–10180 and CMS–
R–199]
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Centers for Medicare &
Medicaid Services, HHS.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
Services (CMS), Department of Health
and Human Services, is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
AGENCY:
E:\FR\FM\26APN1.SGM
26APN1
erowe on DSK2VPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 81 / Friday, April 26, 2013 / Notices
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the Agency’s function;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
1. Type of Information Collection
Request: Revision of a previously
approved collection; Title of
Information Collection: End Stage Renal
Disease (ESRD) Network Semi-Annual
Cost Report Forms and Supporting
Regulations in 42 CFR section 405.2110
and 42 CFR 405.2112; Use: Section
1881(c) of the Social Security Act
establishes End Stage Renal Disease
(ESRD) Network contracts. The
regulations found at 42 CFR 405.2110
and 405.2112 designated 18 ESRD
Networks which are funded by
renewable contracts. These contracts are
on 3-year cycles. To better administer
the program, CMS is requiring
contractors to submit semi-annual cost
reports. The purpose of the cost reports
is to enable the ESRD Networks to
report costs in a standardized manner.
This will allow CMS to review, compare
and project ESRD Network costs during
the life of the contract. Since the last
collection, the survey instrument has
been revised. The burden has not
changed. Form Number: CMS–685
(OMB#: 0938–0657); Frequency:
Reporting—Semi-annually; Affected
Public: Not-for-profit institutions;
Number of Respondents: 18; Total
Annual Responses: 36; Total Annual
Hours: 108. (For policy questions
regarding this collection contact
Benjamin Bernstein at 410–786–6570.
For all other issues call 410–786–1326.)
2. Type of Information Collection
Request: New collection; Title of
Information Collection: Evaluation of
the Multi-Payer Advanced Primary Care
Practice Demonstration; Use: On
September 16, 2009, the Department of
Health and Human Services announced
the establishment of the Multi-Payer
Advanced Primary Care Practice
(MAPCP) Demonstration, under which
Medicare joined Medicaid and private
insurers as a payer participant in statesponsored initiatives to promote the
principles that characterize advanced
primary care, often referred to as the
‘‘patient-centered medical home’’
(PCMH). The CMS selected eight states
to participate in this demonstration:
Maine, Vermont, Rhode Island, New
VerDate Mar<15>2010
14:46 Apr 25, 2013
Jkt 229001
York, Pennsylvania, North Carolina,
Michigan, and Minnesota. These states
vary on a number of important
dimensions, such as features of their
public (Medicaid) and private insurance
markets, delivery system, prior
experience with medical home
initiatives, and nature of their statesponsored multi-payer initiative.
CMS is conducting an evaluation of
the demonstration to assess the effects
of advanced primary care practice when
supported by Medicare, Medicaid, and
private health plans. As part of this
evaluation, qualitative and quantitative
data will be collected and analyzed to
answer research questions focused on:
(1) State initiative features and
implementation, including various
payment models; (2) practice
characteristics, particularly medical
home transformation; and (3) outcomes,
including access to and coordination of
care, clinical quality of care and patient
safety, beneficiary experience with care,
patterns of utilization, Medicare and
Medicaid expenditures, and budget
neutrality.
Subsequent to the publication of the
60-day Federal Register notice (May 31,
2012; 77 FR 32118), the interview
protocols have been revised by adding,
revising and/or deleting questions. Also,
there have been protocols added to the
information collection request. Form
Number: CMS–10436 (OCN: 0938–
New); Frequency: Yearly; Affected
Public: Individuals and households;
Number of Respondents: 472; Total
Annual Responses: 472; Total Annual
Hours: 478 (For policy questions
regarding this collection contact
Suzanne Goodwin at 410–786–0226. For
all other issues call 410–786–1326.)
3. Type of Information Collection
Request: New collection; Title of
Information Collection: CMS Enterprise
Identity Management System; Use: The
Enterprise Identity Management (EIDM)
solution will provide an enterprise-wide
solution that will also support CMS’
senior management goal to improve the
Provider and Health Information
Exchange experience by providing an
enterprise-wide set of credentials and
single sign-on capability for multiple
CMS applications. In order to prove the
identity of an individual requesting
electronic access to CMS protected
information or services, CMS will
collect a core set of attributes about that
individual. These core attributes will be
used to:
1. Provide the identity proofing
service sufficient data to establish that
the individual’s identity is provable to
a NIST assurance level;
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
24753
2. Store the approval information
returned by the identity proofing
service;
3. Provide CMS with additional data
for multi-factor identification (personal
questions and answers);
4. Provide the user a single sign-on,
federated CMS EIDM ID and Password;
5. Authenticate the user; and
6. Authorize the user for application
access.
The information collected will be
gathered and used solely by CMS and
approved contractor(s) and state health
insurance exchanges. Information
confidentiality will conform to HIPAA
and FISMA requirements. Respondents
may also access CMS Terms of Service
and CMS Privacy Statement on the Web.
Form Numbers: CMS–10452 (OCN:
0938–New); Frequency: Reporting—On
occasion; Affected Public: Individuals
and households; Number of Annual
Respondents: 26,000,000; Total Annual
Responses: 26,000,000; Total Annual
Hours: 8,666,667. (For policy questions
regarding this collection contact Robert
Burger at 410–786–2125. For all other
issues call 410–786–1326.)
4. Type of Information Collection
Request: Reinstatement without change
of a previously approved collection;
Title of Information Collection:
Children’s Health Insurance Program
(CHIP) Report on Payables and
Receivables; Use: Collection of
Children’s Health Insurance Program
(CHIP) data and the calculation of the
CHIP Incurred But Not Reported (IBNR)
estimate are pertinent to CMS’ financial
audit. The Chief Financial Officer
auditors have reported the lack of an
estimate for CHIP IBNR payables and
receivables as a reportable condition in
the FY 2005 audit of CMS’s financial
statements. It is essential that CMS
collect the necessary data from State
agencies in FY 2006, so that CMS
continues to receive an unqualified
audit opinion on its financial
statements. Program expenditures for
the CHIP have increased since its
inception; as such, CHIP receivables and
payables may materially impact the
financial statements. The CHIP Report
on Payables and Receivables will
provide the information needed to
calculate the CHIP IBNR; Form Number:
CMS–10180 (OCN: 0938–0988);
Frequency: Reporting—Annually;
Affected Public: State, Local or Tribal
governments; Number of Respondents:
56; Total Annual Responses: 56; Total
Annual Hours: 392. (For policy
questions regarding this collection
contact Michele Myers at 410–786–
7911. For all other issues call 410–786–
1326.)
E:\FR\FM\26APN1.SGM
26APN1
24754
Federal Register / Vol. 78, No. 81 / Friday, April 26, 2013 / Notices
erowe on DSK2VPTVN1PROD with NOTICES
5. Type of Information Collection
Request: Reinstatement without change
of a previously approved collection;
Title of Information Collection:
Medicaid Report on Payables and
Receivables; Use: The Chief Financial
Officers (CFO) Act of 1990, as amended
by the Government Management Reform
Act (GMRA) of 1994, requires
government agencies to produce
auditable financial statements. Because
the Centers for Medicare & Medicaid
Services (CMS) fulfills its mission
through its contractors and the States;
these entities are the primary source of
information for the financial statements.
There are three basic categories of data:
Expenses, payables, and receivables.
The CMS–64 is used to collect data on
Medicaid expenses. The CMS–R–199
collects Medicaid payable and
receivable accounting data from the
States. Form Number: CMS–R–199
(OCN: 0938–0697); Frequency:
Reporting—Annually; Affected Public:
State, Local or Tribal governments;
Number of Respondents: 56; Total
Annual Responses: 56; Total Annual
Hours: 336. (For policy questions
regarding this collection contact
Michele Myers at 410–786–7911. For all
other issues call 410–786–1326.)
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS Web site
address at https://www.cms.hhs.gov/
PaperworkReductionActof1995, or
Email your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov, or call the
Reports Clearance Office on (410) 786–
1326.
To be assured consideration,
comments and recommendations for the
proposed information collections must
be received by the OMB desk officer at
the address below, no later than 5 p.m.
on May 28, 2013. OMB, Office of
Information and Regulatory Affairs,
Attention: CMS Desk Officer, Fax
Number: (202) 395–6974, Email:
OIRA_submission@omb.eop.gov.
Dated: April 23, 2013.
Martique Jones,
Deputy Director, Regulations Development
Group, Office of Strategic Operations and
Regulatory Affairs.
[FR Doc. 2013–09913 Filed 4–25–13; 8:45 am]
BILLING CODE 4120–01–P
VerDate Mar<15>2010
14:46 Apr 25, 2013
Jkt 229001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–D–0800]
Guidance for Industry on Regulatory
Classification of Pharmaceutical CoCrystals; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a guidance for industry
entitled ‘‘Regulatory Classification of
Pharmaceutical Co-Crystals.’’ This
guidance provides applicants of new
drug applications (NDAs) and
abbreviated new drug applications
(ANDAs) with the Center for Drug
Evaluation and Research’s (CDER’s)
current thinking on the appropriate
regulatory classification of
pharmaceutical co-crystal solid-state
forms. This guidance also provides
information about the data the applicant
should submit to support the
appropriate classification of a co-crystal,
as well as the regulatory implications of
the classification.
The recommendations in this
guidance apply to materials that the
Agency has not previously evaluated
and determined to be pharmaceutical
co-crystals. The recommendations do
not apply to materials that the Agency
has previously designated as salts,
complexes, or other non-co-crystalline
forms.
SUMMARY:
Submit either electronic or
written comments on Agency guidances
at any time.
ADDRESSES: Submit written requests for
single copies of this guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201,
Silver Spring, MD 20993–0002. Send
one self-addressed adhesive label to
assist that office in processing your
requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the guidance document.
Submit electronic comments on the
guidance to https://www.regulations.gov.
Submit written comments to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
FOR FURTHER INFORMATION CONTACT:
Andre Raw, Center for Drug Evaluation
and Research, Food and Drug
Administration, Metro Park North II,
DATES:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
7500 Standish Pl., Rockville, MD
20855, 240–276–8500; or
Richard Lostritto, Center for Drug
Evaluation and Research, Food and
Drug Administration, Bldg. 21, rm.
1626, 10903 New Hampshire Ave.,
Silver Spring, MD 20993, 301–796–
1900.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a guidance for industry entitled
‘‘Regulatory Classification of
Pharmaceutical Co-Crystals.’’ This
guidance provides applicants of NDAs
and ANDAs with CDER’s current
thinking on the appropriate regulatory
classification of pharmaceutical cocrystal solid-state forms. This guidance
also provides information about the data
the applicant should submit to support
the appropriate classification of a cocrystal, as well as the regulatory
implications of the classification.
On December 2, 2011 (76 FR 75551),
FDA announced the availability of the
draft version of this guidance. The
public comment period closed on March
1, 2012. A number of comments were
received from the public, all of which
the Agency considered carefully as it
finalized the guidance and made
appropriate changes. Any changes to the
guidance were minor and made to
clarify statements in the draft guidance.
Co-crystals are solids that are
crystalline materials composed of two or
more molecules in the same crystal
lattice. These solid-state forms,
composed of an active pharmaceutical
ingredient (API) with a neutral guest
compound (also referred to as a
conformer), have been the focus of
significant interest in drug product
development. Pharmaceutical cocrystals have opened the opportunity for
engineering solid-state forms designed
to have tailored properties to enhance
drug product bioavailability and
stability, as well as enhance
processability of the solid material
inputs in drug product manufacture.
Pharmaceutical co-crystals are of
interest because they offer the advantage
of generating a diverse array of solidstate forms from APIs that lack ionizable
functional groups needed for salt
formation.
Traditionally, solid-state polymorphic
forms of an API are classified as either
crystalline, amorphous, or solvate and
hydrate forms, and applicable regulatory
schemes for these solid-state
polymorphic forms are well-defined.
Co-crystals, however, are
distinguishable from these traditional
pharmaceutical solid-state forms. Unlike
E:\FR\FM\26APN1.SGM
26APN1
]]>Agencies
[Federal Register Volume 78, Number 81 (Friday, April 26, 2013)]
[Notices]
[Pages 24752-24754]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-09913]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifiers CMS-685, CMS-10436, CMS-10452, CMS-10180 and CMS-
R-199]
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
AGENCY: Centers for Medicare & Medicaid Services, HHS.
In compliance with the requirement of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the Centers for Medicare & Medicaid
Services (CMS), Department of Health and Human Services, is publishing
the following summary of proposed collections for public comment.
Interested persons are invited to send comments regarding this burden
[[Page 24753]]
estimate or any other aspect of this collection of information,
including any of the following subjects: (1) The necessity and utility
of the proposed information collection for the proper performance of
the Agency's function; (2) the accuracy of the estimated burden; (3)
ways to enhance the quality, utility, and clarity of the information to
be collected; and (4) the use of automated collection techniques or
other forms of information technology to minimize the information
collection burden.
1. Type of Information Collection Request: Revision of a previously
approved collection; Title of Information Collection: End Stage Renal
Disease (ESRD) Network Semi-Annual Cost Report Forms and Supporting
Regulations in 42 CFR section 405.2110 and 42 CFR 405.2112; Use:
Section 1881(c) of the Social Security Act establishes End Stage Renal
Disease (ESRD) Network contracts. The regulations found at 42 CFR
405.2110 and 405.2112 designated 18 ESRD Networks which are funded by
renewable contracts. These contracts are on 3-year cycles. To better
administer the program, CMS is requiring contractors to submit semi-
annual cost reports. The purpose of the cost reports is to enable the
ESRD Networks to report costs in a standardized manner. This will allow
CMS to review, compare and project ESRD Network costs during the life
of the contract. Since the last collection, the survey instrument has
been revised. The burden has not changed. Form Number: CMS-685
(OMB: 0938-0657); Frequency: Reporting--Semi-annually;
Affected Public: Not-for-profit institutions; Number of Respondents:
18; Total Annual Responses: 36; Total Annual Hours: 108. (For policy
questions regarding this collection contact Benjamin Bernstein at 410-
786-6570. For all other issues call 410-786-1326.)
2. Type of Information Collection Request: New collection; Title of
Information Collection: Evaluation of the Multi-Payer Advanced Primary
Care Practice Demonstration; Use: On September 16, 2009, the Department
of Health and Human Services announced the establishment of the Multi-
Payer Advanced Primary Care Practice (MAPCP) Demonstration, under which
Medicare joined Medicaid and private insurers as a payer participant in
state-sponsored initiatives to promote the principles that characterize
advanced primary care, often referred to as the ``patient-centered
medical home'' (PCMH). The CMS selected eight states to participate in
this demonstration: Maine, Vermont, Rhode Island, New York,
Pennsylvania, North Carolina, Michigan, and Minnesota. These states
vary on a number of important dimensions, such as features of their
public (Medicaid) and private insurance markets, delivery system, prior
experience with medical home initiatives, and nature of their state-
sponsored multi-payer initiative.
CMS is conducting an evaluation of the demonstration to assess the
effects of advanced primary care practice when supported by Medicare,
Medicaid, and private health plans. As part of this evaluation,
qualitative and quantitative data will be collected and analyzed to
answer research questions focused on: (1) State initiative features and
implementation, including various payment models; (2) practice
characteristics, particularly medical home transformation; and (3)
outcomes, including access to and coordination of care, clinical
quality of care and patient safety, beneficiary experience with care,
patterns of utilization, Medicare and Medicaid expenditures, and budget
neutrality.
Subsequent to the publication of the 60-day Federal Register notice
(May 31, 2012; 77 FR 32118), the interview protocols have been revised
by adding, revising and/or deleting questions. Also, there have been
protocols added to the information collection request. Form Number:
CMS-10436 (OCN: 0938-New); Frequency: Yearly; Affected Public:
Individuals and households; Number of Respondents: 472; Total Annual
Responses: 472; Total Annual Hours: 478 (For policy questions regarding
this collection contact Suzanne Goodwin at 410-786-0226. For all other
issues call 410-786-1326.)
3. Type of Information Collection Request: New collection; Title of
Information Collection: CMS Enterprise Identity Management System; Use:
The Enterprise Identity Management (EIDM) solution will provide an
enterprise-wide solution that will also support CMS' senior management
goal to improve the Provider and Health Information Exchange experience
by providing an enterprise-wide set of credentials and single sign-on
capability for multiple CMS applications. In order to prove the
identity of an individual requesting electronic access to CMS protected
information or services, CMS will collect a core set of attributes
about that individual. These core attributes will be used to:
1. Provide the identity proofing service sufficient data to
establish that the individual's identity is provable to a NIST
assurance level;
2. Store the approval information returned by the identity proofing
service;
3. Provide CMS with additional data for multi-factor identification
(personal questions and answers);
4. Provide the user a single sign-on, federated CMS EIDM ID and
Password;
5. Authenticate the user; and
6. Authorize the user for application access.
The information collected will be gathered and used solely by CMS and
approved contractor(s) and state health insurance exchanges.
Information confidentiality will conform to HIPAA and FISMA
requirements. Respondents may also access CMS Terms of Service and CMS
Privacy Statement on the Web. Form Numbers: CMS-10452 (OCN: 0938-New);
Frequency: Reporting--On occasion; Affected Public: Individuals and
households; Number of Annual Respondents: 26,000,000; Total Annual
Responses: 26,000,000; Total Annual Hours: 8,666,667. (For policy
questions regarding this collection contact Robert Burger at 410-786-
2125. For all other issues call 410-786-1326.)
4. Type of Information Collection Request: Reinstatement without
change of a previously approved collection; Title of Information
Collection: Children's Health Insurance Program (CHIP) Report on
Payables and Receivables; Use: Collection of Children's Health
Insurance Program (CHIP) data and the calculation of the CHIP Incurred
But Not Reported (IBNR) estimate are pertinent to CMS' financial audit.
The Chief Financial Officer auditors have reported the lack of an
estimate for CHIP IBNR payables and receivables as a reportable
condition in the FY 2005 audit of CMS's financial statements. It is
essential that CMS collect the necessary data from State agencies in FY
2006, so that CMS continues to receive an unqualified audit opinion on
its financial statements. Program expenditures for the CHIP have
increased since its inception; as such, CHIP receivables and payables
may materially impact the financial statements. The CHIP Report on
Payables and Receivables will provide the information needed to
calculate the CHIP IBNR; Form Number: CMS-10180 (OCN: 0938-0988);
Frequency: Reporting--Annually; Affected Public: State, Local or Tribal
governments; Number of Respondents: 56; Total Annual Responses: 56;
Total Annual Hours: 392. (For policy questions regarding this
collection contact Michele Myers at 410-786-7911. For all other issues
call 410-786-1326.)
[[Page 24754]]
5. Type of Information Collection Request: Reinstatement without
change of a previously approved collection; Title of Information
Collection: Medicaid Report on Payables and Receivables; Use: The Chief
Financial Officers (CFO) Act of 1990, as amended by the Government
Management Reform Act (GMRA) of 1994, requires government agencies to
produce auditable financial statements. Because the Centers for
Medicare & Medicaid Services (CMS) fulfills its mission through its
contractors and the States; these entities are the primary source of
information for the financial statements. There are three basic
categories of data: Expenses, payables, and receivables. The CMS-64 is
used to collect data on Medicaid expenses. The CMS-R-199 collects
Medicaid payable and receivable accounting data from the States. Form
Number: CMS-R-199 (OCN: 0938-0697); Frequency: Reporting--Annually;
Affected Public: State, Local or Tribal governments; Number of
Respondents: 56; Total Annual Responses: 56; Total Annual Hours: 336.
(For policy questions regarding this collection contact Michele Myers
at 410-786-7911. For all other issues call 410-786-1326.)
To obtain copies of the supporting statement and any related forms
for the proposed paperwork collections referenced above, access CMS Web
site address at https://www.cms.hhs.gov/PaperworkReductionActof1995, or
Email your request, including your address, phone number, OMB number,
and CMS document identifier, to Paperwork@cms.hhs.gov, or call the
Reports Clearance Office on (410) 786-1326.
To be assured consideration, comments and recommendations for the
proposed information collections must be received by the OMB desk
officer at the address below, no later than 5 p.m. on May 28, 2013.
OMB, Office of Information and Regulatory Affairs, Attention: CMS Desk
Officer, Fax Number: (202) 395-6974, Email: OIRA_submission@omb.eop.gov.
Dated: April 23, 2013.
Martique Jones,
Deputy Director, Regulations Development Group, Office of Strategic
Operations and Regulatory Affairs.
[FR Doc. 2013-09913 Filed 4-25-13; 8:45 am]
BILLING CODE 4120-01-P
